Insider Selling: InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells 20,000 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the sale, the chief executive officer now directly owns 436,659 shares in the company, valued at approximately $4,069,661.88. The trade was a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The shares were sold at an average price of $8.87, for a total value of $47,880.26.

InfuSystem Price Performance

Shares of NYSE:INFU opened at $8.86 on Friday. The company’s 50 day simple moving average is $7.29. InfuSystem Holdings, Inc. has a 1 year low of $5.74 and a 1 year high of $10.99. The stock has a market cap of $188.40 million, a price-to-earnings ratio of 147.67 and a beta of 1.45. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50.

Analyst Upgrades and Downgrades

Several research firms recently commented on INFU. B. Riley initiated coverage on shares of InfuSystem in a research report on Thursday, September 26th. They set a “buy” rating and a $13.00 price target on the stock. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th.

Hedge Funds Weigh In On InfuSystem

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares in the last quarter. Williams & Novak LLC acquired a new stake in InfuSystem in the 3rd quarter worth about $70,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in InfuSystem during the 3rd quarter worth approximately $87,000. Rhumbline Advisers raised its holdings in shares of InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after acquiring an additional 2,145 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of InfuSystem in the second quarter valued at approximately $131,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.